Scientists from the University of Copenhagen say he has developed a medicine Which reduces appetite while increasing calorie burning – without any symptoms of nausea,
“Although GLP-1-based therapies have revolutionized the care of patients with obesity and type 2 diabetes, reducing energy expenditure safely and without nausea,” said Zach Gerhart-Hines of the Novo Nordisk Foundation Center for BASIC. Controlling hunger remains two sacred things in this area.” Metabolic Research at the University of Copenhagen.
Ozempic is part of a class of diabetes and obesity medications that mimic the GLP-1 hormone that the body naturally produces after eating, suppressing appetite and inducing weight loss.
Scientists at the University of Copenhagen, funded by Ozempic maker Novo Nordisk, wanted to see if they could create a drug that reduced appetite and increased calorie burning.
They discovered more than 380 G protein-coupled receptors – which receive signals from hormones and other stimuli to activate proteins, thereby initiating a cellular response in the body – and identified them based on their association with HbA1c. Which is a key indicator of blood sugar regulation and progression of diabetes,
Researchers believe they have found their answer in the neurokinin 2 receptor (NK2R) after uncovering genetic links to obesity and blood sugar control.
NK2R has been studied for its role in the gastrointestinal tract and central nervous system, but the study authors believe it has not previously been linked to blood sugar regulation or cardiometabolic health,
Researchers at the University of Copenhagen say scientists have not been able to effectively harness the NK2R signaling pathway because its natural activator is quickly broken down in the body and can bind to receptors other than NK2R, causing interactions with drugs. It becomes difficult to exploit it.
So they developed selective, long-acting NK2R agonists, which they found increased calorie burning and reduced appetite in mice without any symptoms of nausea.
In diabetic, obese macaques, NK2R activation significantly reduced body weight, blood sugar, harmful triglycerides, and cholesterol while improving insulin sensitivity.
“One of the biggest hurdles in drug development is translation between mice and humans,” said study author Frederick Sass. “That’s why we were excited that the benefit of NK2R agonism was found in non-human primates with diabetes and obesity, which represents a major step toward clinical translation.”
It will still take a long time for the once-a-week injection to get into consumer hands. Gerhart-Hines told The Post that her team plans to begin clinical trials within the next year. It will probably take five or six years for the drug to be available to the public.
Conclusions of the study – Published in Nature on Wednesday , Follow a recent survey It found that about 12% of American adults have used a GLP-1 drug like Ozempic or Mounjaro,
Of concern to physicians is that an estimated 50% to 75% of people People who start taking GLP-1 medications stop using them within a year. Some people have reported Factors such as cost and side effects such as nausea.
However, others quit because they achieved their weight loss goals regaining weight is common When you stop taking the medicines.
Northwestern Medicine Cardiologist Dr. Saadia Khan Among those calling for more research In ways to support long-term use.
“The dissection rate of GLP-1 is surprisingly high [drugs] “This should raise concerns for physicians, policymakers and public health experts,” Khan said Wednesday.
